VVA
ALLO icon

Vida Ventures Advisors’s Allogene Therapeutics ALLO Stock Holding History

Vida Ventures Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.23M Hold
1,798,163
– – 7.59% 2
2025
Q2 		$2.03M Hold
1,798,163
– – 12.76% 2
2025
Q1 		$2.63M Hold
1,798,163
– – 19.25% 2
2024
Q4 		$3.83M Hold
1,798,163
– – 2.62% 5
2024
Q3 		$5.03M Hold
1,798,163
– – 3.63% 5
2024
Q2 		$4.19M Hold
1,798,163
– – 4.58% 4
2024
Q1 		$8.04M Hold
1,798,163
– – 4.47% 4
2023
Q4 		$5.77M Hold
1,798,163
– – 6.87% 4
2023
Q3 		$5.7M Hold
1,798,163
– – 8.82% 3
2023
Q2 		$8.94M Hold
1,798,163
– – 11.67% 3
2023
Q1 		$8.88M Hold
1,798,163
– – 12.15% 4
2022
Q4 		$11.3M Hold
1,798,163
– – 15.2% 4
2022
Q3 		$19.4M Hold
1,798,163
– – 17.43% 3
2022
Q2 		$20.5M Hold
1,798,163
– – 17.32% 2
2022
Q1 		$16.4M Hold
1,798,163
– – 9.53% 6
2021
Q4 		$26.8M Hold
1,798,163
– – 10.04% 6
2021
Q3 		$46.2M Hold
1,798,163
– – 13.24% 6
2021
Q2 		$46.9M Hold
1,798,163
– – 11.76% 6
2021
Q1 		$63.5M Hold
1,798,163
– – 16.04% 4
2020
Q4 		$45.4M Hold
1,798,163
– – 9.32% 5
2020
Q3 		$67.8M Buy
+1,798,163
New +$67.8M 42.47% 1

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vida Ventures Advisors's ALLO Position: Q3 2025 in Review

Vida Ventures Advisors held its Allogene Therapeutics (ALLO) position steady in Q3 2025 at 1,798,163 shares worth $2.23M. The position accounts for 7.59% of the portfolio, ranked #2.

Vida Ventures Advisors first reported a position in ALLO in Q3 2020 and has held it in 21 quarters since. The position peaked at $67.8M in Q3 2020. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Vida Ventures Advisors held 1,798,163 shares of Allogene Therapeutics worth $2.23M as of Q3 2025.
  • Vida Ventures Advisors left its Allogene Therapeutics share count unchanged in Q3 2025.
  • Allogene Therapeutics made up 7.59% of Vida Ventures Advisors's portfolio in Q3 2025, its #2 holding.
  • Vida Ventures Advisors first reported a position in Allogene Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Vida Ventures Advisors's Allogene Therapeutics position peaked at $67.8M in Q3 2020.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Vida Ventures Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.